NeuroVive Pharmaceutical AB Price/Book
What is the Price/Book of NeuroVive Pharmaceutical AB?
The Price/Book of NeuroVive Pharmaceutical AB is 4.20
What is the definition of Price/Book?
Price to book ratio represents the ratio between a company’s stock value and the book value per share.
mrq (most recent quarter)
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book of companies in the Miscellaneous sector on LSE compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with price/book similar to NeuroVive Pharmaceutical AB
- Mattel has Price/Book of 4.20
- Somfy SA has Price/Book of 4.20
- Cloudera Inc has Price/Book of 4.20
- Eagle Materials has Price/Book of 4.20
- SECOS has Price/Book of 4.20
- GoldQuest Mining has Price/Book of 4.20
- NeuroVive Pharmaceutical AB has Price/Book of 4.20
- Keywords Studios plc has Price/Book of 4.20
- Prairie Mining has Price/Book of 4.21
- Atul Auto has Price/Book of 4.21
- The Gap has Price/Book of 4.21
- Great Panther Mining has Price/Book of 4.21
- Uniti has Price/Book of 4.21